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This  study  investigated  the  association  of  ongoing 
West Nile virus (WNV) infections with neutralizing antibody 
titers in US plasma-derived intravenous immune globulin 
released during 2003–2008. Titers correlated closely with 
the prevalence of past WNV infection in blood donors, with 
2008 lots indicating a prevalence of 1%.
W
est Nile virus (WNV) is a flavivirus endemic to the 
United States; typically, hundreds of clinical cases 
of infection occur each year. The observed number of clini-
cal WNV infections as collated by ArboNET (www.cdc.
gov) and the incidence of asymptomatic WNV infections 
as shown by nucleic acid testing (NAT) of the US blood 
supply (1) indicate that ≈3 million WNV infections oc-
curred in humans during 1999– 2008.
Because the immune system elicits WNV neutraliz-
ing antibodies in response to WNV infection, detectable 
levels of WNV neutralizing antibodies in the blood of 
persons with previous WNV infection is expected. Con-
sequently, lots of immune globulin-intravenous (human) 
(IGIV) manufactured from plasma collected in the United 
States contain WNV neutralizing antibodies (2). Those 
IGIV lots, each prepared from several thousand plasma 
donations to ensure a broad spectrum of antibodies, can 
be used as an epidemiologic tool that enables the surveil-
lance of thousands of persons in a community through 
analysis of comparatively few samples. In this study, we 
demonstrated the increasing trend of WNV-neutralizing 
antibody titers in lots of IGIV.
Comparing  these  titers  with  those  of  persons  with 
confirmed past WNV infection provides an independent 
measure of the percentage of the US population previously 
infected with WNV. Several WNV vaccine trials are ongo-
ing or imminent, so information about the prevalence of 
past WNV infection in the United States is valuable for 
planning the demonstration of vaccine efficacy. Low inci-
dence and lack of highly WNV-endemic areas in the United 
States preclude classic vaccine field trials because of study 
size requirements and cost-logistics difficulties. 
The Study
The WNV neutralization titers of several US plasma–
derived  IGIV  products  (Gammagard  Liquid/KIOVIG; 
Gammagard  S/D/  Polygam  S/D;  Iveegam  EN  [Baxter 
Healthcare  Corporation,  Westlake  Village,  CA,  USA]) 
and plasma samples obtained from US blood donors after 
a NAT-confirmed WNV infection were determined by an 
infectivity assay as earlier described (2), adapted to a clas-
sical microneutralization format (3). WNV neutralization 
titers (i.e., the reciprocal dilution of a 1:2 series resulting 
in 50% neutralization [NT50; detection limits <0.8 for un-
diluted IGIVs and <7.7 for 1:10 prediluted serum]) are re-
ported as the mean ± SEM. An unpaired t test was used to 
evaluate whether titer differences between 2 groups were 
statistically significant. 
Using an extrapolation derived from screening the 
US blood supply for WNV (1), we calculated the average 
annual number of WNV infections in the United States 
for 1999–2008. The total number of neuroinvasive cases 
reported for those years to the US Centers for Disease 
Control  and  Prevention  (CDC)  through  ArboNET  was 
multiplied by 256 (i.e., the factor between all WNV infec-
tions and neuroinvasive cases). The cumulative infection 
rate for each year during 1999–2008 was then calculated 
by dividing the infections occurring up to a specific year 
by the US population for that year (determined by US 
Census Bureau estimates [www.census.gov/popest/states/
NST-ann-est.html]).
Although WNV was first introduced into the United 
States in 1999, only in 2003 did the mean WNV neutral-
ization titers of IGIV lots released to the market start to 
increase  markedly  (Figure  1).  According  to  extrapola-
tions from the WNV screening of the US blood supply 
(1), by 2003, an estimated 0.5% of the US population had 
been infected with WNV, although most infections were   
asymptomatic. 
A delay of ≈1 year occurs between the collection of 
plasma and the release of IGIV lots to the market; thus, the 
WNV-positive IGIV lots in 2003 reflect the larger number 
of WNV infections occurring in 2002. Using the same ex-
trapolations from the US blood supply (1), we found that 
the ≈0.1% annual increments in the proportion of the US 
population with past WNV infection follow a straight line 
(r2 = 0.9996), generally paralleled by the mean WNV neu-
tralization titers of IGIV lots. During 2005–2008, when 
large numbers of lots of a single IGIV product (Gammagard 
Liquid) could be analyzed, the WNV neutralization titer in-
creased by 3.6 per year (r2 = 0.9793).
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US  plasma-derived  IGIV  lots  released  during  2008 
showed variable WNV neutralization titers ranging from 
2.8 to 69.8; mean ± SEM titer was 21 ± 1 (n = 256) (Fig-
ure 2). Compared with titers shown to be protective in an 
animal model of WNV infection (equivalent to >21 by the 
current assay) (2), ≈40% of the 2008 IGIV lots had higher 
titers.
Plasma obtained from persons with NAT-confirmed 
WNV infection had even higher titers; mean ± SEM titer 
was 208 ± 40 for 30 persons available for testing. When 
results were corrected for the immunoglobulin (Ig) G con-
centration in plasma (≈1%), compared with the 10% IGIV 
preparations, the mean neutralization titer of the plasma 
samples was ≈100× higher than that of the IGIV lots tested 
(2,080 vs. 21).
Conclusions
The  most  comprehensive  collation  of  information 
about the incidence of WNV infection in the United States 
is  available  from  ArboNET.  When  that  information  is 
combined with information obtained from the nationwide 
screening of the blood supply for WNV RNA by NAT 
(1,4,5), the current prevalence of past WNV in the US pop-
ulation is estimated to be  ≈1%.
Busch et al. has noted that large-scale, community-
based serologic surveys are hardly feasible because of their 
expense and because WNV ELISA assays are possibly bi-
ased by  cross-reactions with other flaviviruses (1). Never-
theless, 7 seroepidemiologic studies have been performed 
(6–12). Cumulatively, 5,503 persons were tested for WNV 
infection by ELISA, and the results have shown highly di-
vergent seroprevalence rates ranging between 1.9% (6) and 
14.0% (10).
The use of IGIV lots, each representing the serostatus 
of several thousand donors in 1 sample, makes seroepi-
demiology practical (13) because it allows a large donor 
population to be surveyed by analyzing comparably few 
samples. The use of a more complex yet functional virus 
neutralization assay minimizes concerns about cross-reac-
tivity with flaviviruses of other serocomplexes (e.g., den-
gue virus) that occasionally circulate in the US population. 
Also, epidemiologic considerations render interference by 
St. Louis encephalitis virus, a flavivirus within the same se-
rocomplex, highly unlikely (2). The specificity of the neu-
tralization assay was confirmed by testing IGIV lots manu-
factured from European-derived plasma against tick-borne 
encephalitis virus, a flavivirus closely related to WNV and 
circulating in Europe. Although these lots contained high 
neutralization titers against tick-borne encephalitis virus, 
only 1 of 20 had a detectable neutralization titer of 5 against 
WNV (unpub. data).
In this study, we determined that the mean titer of 
samples obtained during 2003–2008 from persons with a 
confirmed diagnosis of WNV infection was 100× higher 
than the mean titers of IGIV lots produced in 2008. This 
determination provides an independent experimental mea-
sure of the frequency of past WNV infection in the gen-
eral US population, as reflected by the plasma/blood donor 
community, and the results correlate well with results of 
previously published theoretical extrapolations (1), which 
estimated that ≈1% of the population has already been in-
fected with WNV.
The increasing levels of WNV neutralizing antibod-
ies in IGIV lots from US plasma and the particularly high 
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Figure 1. West Nile virus (WNV) neutralization titers of US plasma-
derived immune globulin intravenous (human) (IGIV) lots by year of 
production and estimated percentage of the US population with past 
WNV infection by year. WNV neutralization titers were determined 
either  for  retention  or  lot  release  samples  of  3  IGIV  products 
produced  during  1998–2005  or  for  a  considerable  proportion  of 
Gammagard  Liquid/KIOVIG  lots  produced  during  2006–2008. 
Results are shown as mean ± SEM (limit of detection <0.8) by year 
of product release. For 5% of IGIV samples, titers were multiplied 
by  2  for  comparison  with  the  10%  IGIV  samples  at  equivalent 
immunoglobulin concentrations. The percentage of the US donor 
population with past WNV infection was calculated from the number 
of neuroinvasive cases reported per year and the estimated ratio of 
neuroinvasive cases to total cases of WNV infection.
Figure  2.  West  Nile  virus  (WNV)  neutralization  by  US  plasma-
derived immune globulin intravenous (human) (IGIV) released in 
2008 and plasma from donors with past WNV infection (past WNV), 
confirmed  by  nucleic  acid  testing.  WNV  neutralization  titers  are 
shown as the mean ± SEM (limit of detection <0.8 for undiluted 
IGIVs and <7.7 for prediluted sera). NT50, 50% neutralization titer.titers in donors who have had a WNV infection suggest 
the possibility of preparing IGIV products with sufficiently 
high titers to be useful for WNV prophylaxis or treatment. 
Several ongoing or imminent WNV vaccine clinical trials 
stress the practical value of an independent confirmation of 
extrapolations that estimate the percentage of the US popu-
lation with past WNV infection. Knowing the percentage 
of preexisting WNV seroprevalence as well as estimates 
of the mostly asymptomatic incidence rates (14) can be of 
vital importance in designing vaccine trials.
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